Executive Summary
This one-day snapshot of 18 high-value federal contracts totaling $2.9B underscores bullish momentum for IT services and health/security contractors, with Leidos securing the largest $1.1B combined awards from SSA and DHS. Firm fixed price structures dominate (12/18), offering revenue visibility but execution risks, while options provide $2B+ upside potential across portfolios.
Institutional investors should prioritize public equities like Leidos (LDOS), OSI Systems (OSIS), and General Dynamics (GD) for steady gov revenue amid long-term extensions to 2033.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior High-Value Federal Grants ($5M+) digest from March 18, 2026.
Investment Signals (4)
- Leidos dominates with $1.13B in IT/maintenance awards (HIGH)▲
Leidos secured top two contracts ($1.06B SSA IT + $67M DHS equipment maintenance), with $906M outlayed and $425M options upside through 2028.
- Health IT/services surge via VA/HHS with $700M+ obligations (HIGH)▲
VA and HHS awards to Oracle ($176M EHRM), Wisconsin Physicians ($319M MAC), Charles River ($96M animal care), and Deloitte ($67M cyber) signal multi-year demand, with $1.1B total options.
- DHS/CBP border security hardware/services at $473M (HIGH)▲
Rapiscan ($186M portals), Smiths Detection ($77M rail), Steampunk ($75M HR IT), and Leidos ($67M maintenance) highlight sustained enforcement spending through 2031 potential.
- Nonprofit awards limit equity upside (HIGH)▲
Caltech ($85M NASA) and Refugees Committee ($78M DOI) fully fund nonprofits with minimal public market exposure.
Risk Flags (3)
- Execution [HIGH RISK]▼
Firm fixed price in 12/18 contracts ($2.1B total) exposes winners to cost overruns without reimbursement, especially long-term (e.g., Rapiscan to 2033).
- Competitive [MEDIUM RISK]▼
Non-competed awards (4/18, $429M incl. Oracle VA, GenDyn ED) signal sole-source dependency, vulnerable to future re-competitions.
- Market [MEDIUM RISK]▼
Short-term Medline VA awards ($138M for Jan/Feb 2026) with $0 outlayed risk non-renewal amid VA budget shifts.
Opportunities (3)
- ◆
$2B+ in unexercised options (e.g., Oracle $608M, Salient $150M, Leidos DHS $183M) across IT/health contracts.
- ◆
Extensions to 2029-2033 in 8 contracts ($900M+ incl. Rapiscan, Life Science, Steampunk) amid sustained DHS/HHS needs.
- ◆
High outlays (avg. 50% on $2.9B) in mature contracts (e.g., Leidos SSA 82% outlayed) provide near-term cash flow visibility.
Sector Themes (2)
- ◆
NAICS 5415xx dominates (Leidos, Oracle, Salient, GenDyn, Steampunk) for civilian/defense apps, signaling federal digital transformation priority.
- ◆
Border tech (DHS/CBP $473M) and VA medical ($250M+) reflect resilient spending despite budgets.
Watch List (3)
- 👁
{"entity"=>"Leidos (LDOS)", "reason"=>"Largest winner at $1.13B (39% of total), with $425M options and dual-agency exposure.", "trigger"=>"Q1 earnings citing SSA/DHS ramp-up or option news"}
- 👁
{"entity"=>"Medline Industries", "reason"=>"$138M VA prime vendor for 2026, testing repeat monthly pattern.", "trigger"=>"March 2026+ awards confirming annual $800M+ runway"}
- 👁
{"entity"=>"Oracle Health (ORCL)", "reason"=>"$784M ceiling VA EHRM non-competed, $0 outlayed signals ramp potential.", "trigger"=>"Initial outlays or follow-on VA IT awards"}
Get daily alerts with 4 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 18 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: High-Value Federal Grants ($5M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals